Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 20/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11991405 | 1.00 | HCRTR2 (0.38) | HCRTR2 | |
| SCHEMBL22100267 | 0.86 | HCRTR2 (0.31) | HCRTR2 | |
| SCHEMBL10327057 | 0.84 | HCRTR2 (0.36) | HCRTR2 | |
| SCHEMBL10077153 | 0.84 | HCRTR2 (0.36) | HCRTR2 | |
| SCHEMBL25144021 | 0.81 | SHBG (0.30) | — | |
| SCHEMBL20021699 | 0.81 | HCRTR2 (0.39) | HCRTR2 | |
| SCHEMBL24462741 | 0.81 | HCRTR2 (0.39) | HCRTR2 | |
| SCHEMBL25769565 | 0.81 | — | — | |
| SCHEMBL184319 | 0.81 | — | — | |
| SCHEMBL12855787 | 0.81 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11186565-B2 | Aromatic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| US-11034671-B2 | Apoptosis signal-regulating kinase inhibitors and uses thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-06-15 | — | — | US | disclosed |
| US-10968231-B2 | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | SCOHIA PHARMA, INC. (JP) | 2021-04-06 | — | — | US | disclosed |
| US-20200377509-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-03 | — | — | US | disclosed |
| US-20200283404-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-10696666-B2 | Pharmaceutical compounds | CellCentric Limited (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20200039957-A1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-06 | — | — | US | disclosed |
| CN-109642184-A | Product including plastic containers and composition of matter | 西姆莱斯有限公司 | 2019-04-16 | — | — | CN | disclosed |
| US-9676763-B2 | Method of treating Ebola | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2400846-B1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20160024066-A1 | Small Molecule Inhibitors of Ebola and Lassa Fever Viruses and Methods of Use | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2016-01-28 | — | — | US | disclosed |
| US-9193705-B2 | Small molecule inhibitors of ebola and lassa fever viruses and methods of use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-11-24 | — | — | US | disclosed |
| US-8791303-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| US-8791303-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| US-20130231332-A1 | SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-05 | — | — | US | disclosed |
| US-20120178623-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178623-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283404-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF | DAPK1, ATF1, BAD | HCRTR2 4316/4885 |
| US-11186565-B2 | Aromatic compound | GLP1R, GPR119, GPR39 | HCRTR2 1783/4885 |
| US-20160024066-A1 | Small Molecule Inhibitors of Ebola and Lassa Fever Viruses and Methods of Use | LASP1, LAS1L, HSP90B1 | HCRTR2 4542/4885 |
| US-11034671-B2 | Apoptosis signal-regulating kinase inhibitors and uses thereof | DAPK1, ATF1, BAD | HCRTR2 4316/4885 |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | HCRTR2 4090/4885 |
| US-10968231-B2 | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | GLP1R, GPR119, GPR65 | HCRTR2 946/4885 |
| US-20130231332-A1 | SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE | LASP1, LAS1L, HSP90B1 | HCRTR2 4542/4885 |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | HCRTR2 1583/4885 |
| US-20200039957-A1 | AROMATIC COMPOUND | GLP1R, GPR119, GPR39 | HCRTR2 1783/4885 |
| US-20120178623-A1 | NOVEL HERBICIDES | DDT, CBR3, C9 | HCRTR2 69/4885 |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | HCRTR2 1443/4885 |
| US-10696666-B2 | Pharmaceutical compounds | EP300, HDAC1, HDAC11 | HCRTR2 4508/4885 |
| US-20200377509-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GLP1R, GPR119, GPR65 | HCRTR2 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.